New pill could replace shots for Kidney-Related anemia
NCT ID NCT07487727
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests an oral drug called AND017 against standard injected ESA therapy for anemia in people with chronic kidney disease who are not on dialysis. About 240 participants will receive either AND017 or ESA to see which better maintains healthy hemoglobin levels over 27 weeks. The goal is to find a more convenient treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AND017 (oral capsule)
What this could lead to
If successful, AND017 could offer a more convenient oral treatment option for anemia in chronic kidney disease patients who do not need dialysis.
What could go wrong
This is a Phase 3 trial, but results may not confirm superiority or safety over existing treatments. Side effects and individual responses vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA DUE TO CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact